Trial Profile
A Placebo-Controlled Prospective trial of Romiplostim with Telaprevir, Ribavirin, and Peg Interferon-alfa 2a to assess effect to Optimize SVR in patients with Thrombocytopenic Cirrhotics with Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Dec 2015
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary) ; Peginterferon alfa-2a; Ribavirin; Telaprevir
- Indications Hepatitis C; Thrombocytopenia
- Focus Therapeutic Use
- Acronyms RESTRAINT C
- 08 Dec 2015 New trial record